HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference
Management to discuss HCB101 as a clinical anchor, oncology platform expansion, and the emerging HCB206 autoimmune franchise
TAIPEI, SHANGHAI, and SAN FRANCISCO — September 1, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20–21, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.
Executive leadership will present the continued evolution of the Company’s proprietary FBDB™ platform, highlighting clinical progress of the lead candidate HCB101, pipeline expansion across multispecific HCB301 and HCB303 oncology assets, and the emerging HCB206 autoimmune franchise.
Key topics featured in the management presentation include:
- HCB101 — Clinical Anchor: Updated clinical activity for HanchorBio’s lead SIRPα-based macrophage-directed immunotherapy, including an 80% objective response rate (ORR) in the 5.12–8 mg/kg mid-dose cohorts of second-line gastric/gastroesophageal junction (GC/GEJ) cancer treated with ramucirumab and paclitaxel.
Additional clinical activity includes durable partial response beyond 80 weeks with HCB101 monotherapy in advanced HNSCC, a 50% ORR including a complete response in a Taiwan HNSCC study combining HCB101 with PD-1 blockade, and objective responses with prolonged disease control in colorectal cancer.
- Oncology Platform Expansion: Progress across trispecific programs HCB301 (SIRPα, PD-L1, TGFβ) and HCB303 (SIRPα, PD-L1, TIGIT/PVR), together with rational combination strategies incorporating complementary therapeutic modalities including targeted small molecules, vaccines, bispecific immunotherapies, and antibody-drug conjugates (ADCs).
- Autoimmune Franchise: Advancements of HCB206, designed for precision clearance of pathogenic CD20-positive B-cell compartments.
Meet with HanchorBio at Jefferies APAC
Institutional investors, corporate partners, and other healthcare industry participants wishing to schedule a 1-on-1 meeting with HanchorBio may submit a request through the Jefferies APAC Healthcare Conference meeting portal or contact the Company directly at [email protected].
The inaugural Jefferies APAC Healthcare Conference is expected to convene more than 80 leading healthcare companies and facilitate more than 700 meetings, including one-on-one and small-group discussions between institutional investors and senior corporate management.
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on inventing next-generation biologics for cancer and immune-mediated diseases using its proprietary FBDB™ platform.
HanchorBio’s pipeline includes HCB101, its lead SIRPα-based innate immune checkpoint program; HCB301, a clinical-stage trispecific immunotherapy targeting SIRPα, PD-L1, and TGF-β biology; HCB303, a next-generation trispecific program integrating SIRPα, PD-L1, and TIGIT/PVR biology; and additional programs across oncology and immune-mediated diseases.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the clinical development and potential of HCB101, HCB301, HCB303, HCB206, and other product candidates; future development strategies; potential therapeutic characteristics of HanchorBio’s product candidates; and the capabilities and potential of the FBDB™ platform.
These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. Development timelines, regulatory plans, clinical strategies and potential therapeutic applications may change as additional data become available and regulatory interactions occur. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.